With the new classification of chronic myeloproliferative disorders, and the rise of interest in molecularly targeted therapies, this timely text brings together international experts on the topic to discuss the current technologies and their implications for the treatment of patients.
This title comprehensively covers chronic myeloid leukemia and Ph-negative chronic myeloproliferative disorders and is an essential resource for all practitioners in Hematologic Oncology.
|
|
|
vii | |
| Preface |
|
ix | |
| Acknowledgments |
|
xi | |
|
Part I Philadelphia-positive chronic myeloproliferative disorders |
|
|
|
Chronic myeloid leukemia: a historical perspective |
|
|
1 | (16) |
|
|
|
|
|
Cytogenetics and molecular biology of chronic myeloid leukemia |
|
|
17 | (27) |
|
|
|
|
|
Risk stratification models and prognostic variables for chronic myeloid leukemia |
|
|
44 | (11) |
|
|
|
|
|
|
|
|
|
|
|
Clinical aspects of chronic myeloid leukemia |
|
|
55 | (11) |
|
|
|
|
|
Chronic myeloid leukemia: current first-line treatment options |
|
|
66 | (12) |
|
|
|
|
|
|
|
Chronic myeloid leukemia: new targeted therapies |
|
|
78 | (11) |
|
|
|
|
|
|
|
Hematopoietic cell transplantation for chronic myeloid leukemia and myelofibrosis |
|
|
89 | (14) |
|
|
|
|
|
Monitoring response to therapy for patients with chronic myeloid leukemia |
|
|
103 | (15) |
|
|
|
|
|
Immunotherapy in chronic myeloid leukemia |
|
|
118 | (8) |
|
|
|
Potential treatment algorithms and future directions for patients with chronic myeloid leukemia |
|
|
126 | (12) |
|
|
|
|
|
Part II Philadelphia-negative chronic myeloproliferative disorders |
|
|
|
History of BCR-ABL-negative chronic myeloproliferative disorders |
|
|
138 | (5) |
|
|
|
BCR-ABL-negative atypical chronic myeloproliferative disorders |
|
|
143 | (14) |
|
|
|
|
|
|
|
|
|
157 | (13) |
|
|
|
|
|
|
|
170 | (12) |
|
|
|
|
|
Chronic idiopathic myelofibrosis |
|
|
182 | (12) |
|
|
|
|
|
Essential thrombocythemia |
|
|
194 | (14) |
|
|
|
|
|
Transplant options for patients with BCR-ABL-negative chronic myeloproliferative disorders |
|
|
208 | (9) |
|
|
|
Non-transplant therapeutic strategies for patients with BCR-ABL-negative chronic myeloproliferative disorders |
|
|
217 | (10) |
|
|
|
|
| Index |
|
227 | |
TARIQ I MUGHAL is Professor of Medicine and Haematology/Oncology at the University of Texas Southwestern Medical School, Dallas, USA and Consultant Haematologist at Guys & St Thomas Hospitals, London UK
JOHN M. GOLDMAN is Professor of Haematology at Imperial College London, Hammersmith Hospital, London, UK.
Daugiau apie elektronines knygas